High-profile R&D specialist David Lebwohl jumps to new job as CMO of a pioneering CRISPR player; Troubled AMAG Pharmaceuticals taps Scott Myers as CEO
→ Novartis vet David Lebwohl has found a new biotech to ply his trade.
A little more than a year ago, Lebwohl joined the great migration out of Novartis, leaving his post as head of the CAR-T unit in late 2018 to take the CMO job at Semma. Then Vertex snapped up Semma and its cutting-edge work in regenerative medicine and now Lebwohl is headed to CRISPR/Cas9 pioneer Intellia as chief medical officer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.